person · Reporting owner

BUCHI J KEVIN

Disclosed activity across 7 companies

Tapewire entity: 23704
SEC CIK: 0001209726

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alaunos Therapeutics, Inc.ZIOP · Entity 8339	Director	March 04, 2021	May 06, 2021
Amneal Pharmaceuticals, Inc.AMRX · Entity 820	Director	September 17, 2026	September 21, 2026
Ampio Pharmaceuticals, Inc.AMPE · Entity 112383	Director	June 09, 2023	June 13, 2023
BIOSPECIFICS TECHNOLOGIES CORPBSTC · Entity 144844	Director · Chief Executive Officer	October 23, 2019	October 25, 2019
Benitec Biopharma Inc.BNTC · Entity 5596	Director	June 29, 2026	June 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alaunos Therapeutics, Inc.

Report date March 04, 2021 · Filed May 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,167	Reported balance After 2021-03-04 transaction · row 1 1 source row Row 1 · 2021-03-04 · Grant · Acquired 4,167 · Balance 4,167 F1: The shares will vest on 5/19/2021.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2031-03-03	Direct	31,250	Reported balance After 2021-03-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-03-04 · Grant · Acquired 31,250 · Balance 31,250 F2: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021.

Filing footnotes · ownership attribution and instrument terms

F1: The shares will vest on 5/19/2021.

F2: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021.

Amneal Pharmaceuticals, Inc.

Report date September 17, 2026 · Filed September 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	75,077	Reported balance After 2026-09-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-17 · Gift · Disposed 20,445 · Balance 75,077 F1: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.
Class A Common StockSEC Table I · non-derivative	IndirectBy Trust	113,944	Reported balance Holding disclosure · report date 2026-09-17 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 113,944 F1: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.

Filing footnotes · ownership attribution and instrument terms

F1: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.

Ampio Pharmaceuticals, Inc.

Report date June 09, 2023 · Filed June 13, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	146,858	Reported balance After 2023-06-09 transaction · row 1 1 source row Row 1 · 2023-06-09 · Purchase · Acquired 21,858 · Balance 146,858 F1: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.2751 to $0.30, inclusive.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.2751 to $0.30, inclusive.

BIOSPECIFICS TECHNOLOGIES CORP

Report date October 23, 2019 · Filed October 25, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.52 · Expires 2029-10-23	Direct	85,000	Reported balance After 2019-10-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-10-23 · Grant · Acquired 85,000 · Balance 85,000 F1: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. F2: The stock options vest ratably over the four-year period following the date of grant, October 23, 2019, subject to the Reporting Person's continued service to the employer through the vesting date. In the event the Reporting Person is terminated (a) by the employer without cause, (b) by the Reporting Person for good reason, or (c) by the employer without cause or by the Reporting Person for good reason, in each case upon or within one (1) year following a change of control, the stock options will fully vest.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan.

F2: The stock options vest ratably over the four-year period following the date of grant, October 23, 2019, subject to the Reporting Person's continued service to the employer through the vesting date. In the event the Reporting Person is terminated (a) by the employer without cause, (b) by the Reporting Person for good reason, or (c) by the employer without cause or by the Reporting Person for good reason, in each case upon or within one (1) year following a change of control, the stock options will fully vest.

Benitec Biopharma Inc.

Report date June 29, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	52,097	Reported balance After 2026-06-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-29 · Gift · Disposed 51,813 · Balance 52,097 F1: The reporting person transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a charitable organization under Section 501(c)(3) of the Internal Revenue Code.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a charitable organization under Section 501(c)(3) of the Internal Revenue Code.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dicerna Pharmaceuticals Inc

Report date December 28, 2021 · Filed December 29, 2021

Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-12-28 transaction · row 1 1 source row Row 1 · 2021-12-28 · Other · Disposed 4,666 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.13	Direct	Reported balance After 2021-12-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-28 · Disposition to issuer · Disposed 8,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.76	Direct	Reported balance After 2021-12-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44	Direct	Reported balance After 2021-12-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-12-28 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61	Direct	Reported balance After 2021-12-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-28 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47	Direct	Reported balance After 2021-12-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

Impax Laboratories, LLC

Report date May 04, 2018 · Filed May 08, 2018

Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-04 transaction · row 1 1 source row Row 1 · 2018-05-04 · Disposition to issuer · Disposed 8,020 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
Restricted Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-04 transaction · row 2 1 source row Row 2 · 2018-05-04 · Disposition to issuer · Disposed 3,281 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16	Direct	Reported balance After 2018-05-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-05-04 · Disposition to issuer · Disposed 7,931 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.45 · Expires 2026-11-23	Direct	Reported balance After 2018-05-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-04 · Disposition to issuer · Disposed 20,445 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").

F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.

F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 17, 2026 Filed Sep 21, 2026 20:33 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GiftClass A Common Stock	20,445	$0.00	$0.00	Disclosure SEC source: 0001628280-26-062915 · wk-form4_1790022803.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,077 F1 · kind: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust. F1 · ownership.direct: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust. Read SEC document
September 11, 2026 Filed Sep 14, 2026 20:10 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionStock Option · Derivative	20,445	$0.00 Strike: $14.45	$0.00	Disclosure SEC source: 0001628280-26-061836 · wk-form4_1789416635.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,445 shares Expires 2026-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document
September 11, 2026 Filed Sep 14, 2026 20:10 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	20,445	$14.45	$295,430.25	Disclosure SEC source: 0001628280-26-061836 · wk-form4_1789416635.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2026 Filed Aug 13, 2026 20:21 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	168,573	$17.18	$2,896,084.14	Disclosure SEC source: 0001628280-26-056752 · wk-form4_1786652460.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 93,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. Read SEC document
June 29, 2026 Filed Jun 30, 2026 20:20 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GiftCommon Stock	51,813	$0.00	$0.00	Disclosure SEC source: 0001193125-26-290586 · ownership.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,097 F1 · balance_after: The reporting person transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a charitable organization under Section 501(c)(3) of the Internal Revenue Code. Read SEC document
May 07, 2026 Filed May 8, 2026 20:29 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionRestricted Stock Units · Derivative	34,819	$0.00	$0.00	Disclosure SEC source: 0001628280-26-032929 · wk-form4_1778272151.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. F2 · derivative.expiration_date: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Read SEC document
May 07, 2026 Filed May 8, 2026 20:29 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	34,819	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-26-032929 · wk-form4_1778272151.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document
May 06, 2026 Filed May 8, 2026 20:29 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GrantRestricted Stock Units · Derivative	19,824	$0.00	$0.00	Disclosure SEC source: 0001628280-26-032929 · wk-form4_1778272151.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,824 Underlying: Class A Common Stock · 19,824 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document
December 01, 2025 Filed Dec 3, 2025 21:16 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GrantOptions (right to buy) · Derivative	35,000	$0.00 Strike: $12.23	$0.00	Disclosure SEC source: 0001012975-25-000847 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-12-01 F1 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026. Read SEC document
May 06, 2025 Filed May 8, 2025 23:54 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GrantRestricted Stock Units · Derivative	34,819	$0.00	$0.00	Disclosure SEC source: 0001628280-25-024004 · wk-form4_1746748442.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,819 Underlying: Class A Common Stock · 34,819 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document
May 05, 2025 Filed May 8, 2025 23:54 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionRestricted Stock Units · Derivative	40,258	$0.00	$0.00	Disclosure SEC source: 0001628280-25-024004 · wk-form4_1746748442.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. F2 · derivative.expiration_date: On May 2, 2024, the reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. Read SEC document
May 05, 2025 Filed May 8, 2025 23:54 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	40,258	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-024004 · wk-form4_1746748442.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document
March 12, 2025 Filed Mar 13, 2025 20:43 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GiftCommon Stock	103,626	$0.00	$0.00	Disclosure SEC source: 0001062993-25-005393 · form4.xml · nonDerivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 103,626 F1 · ownership.nature: On March 12, 2025, the reporting person gifted 103,626 shares of Common Stock to a trust for no consideration. The reporting person is trustee of the trust and the reporting person's son is the sole beneficiary. Read SEC document
March 12, 2025 Filed Mar 13, 2025 20:43 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GiftCommon Stock	103,626	$0.00	$0.00	Disclosure SEC source: 0001062993-25-005393 · form4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284 Read SEC document
March 10, 2025 Filed Mar 12, 2025 20:11 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GiftClass A Common Stock	262,072	$0.00	$0.00	Disclosure SEC source: 0001628280-25-012344 · wk-form4_1741810301.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2025, reporting person gifted 262,072 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust, and the son of the reporting person is the sole beneficiary. F1 · ownership.direct: On March 10, 2025, reporting person gifted 262,072 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust, and the son of the reporting person is the sole beneficiary. Read SEC document
February 27, 2025 Filed Mar 3, 2025 19:20 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	Exercise / conversionCommon Warrants (right to buy) · Derivative	51,813	$0.00 Strike: $3.86	$0.00	Disclosure SEC source: 0001062993-25-004077 · form4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,813 shares Expires 2028-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2025 Filed Mar 3, 2025 19:20 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	Exercise / conversionCommon Stock	51,813	$3.86	$199,998.18	Disclosure SEC source: 0001062993-25-004077 · form4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 09, 2024 Filed Dec 11, 2024 22:22 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GrantOptions (right to buy) · Derivative	35,000	$0.00 Strike: $12.18	$0.00	Disclosure SEC source: 0001062993-24-020468 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025. Read SEC document
May 10, 2024 Filed May 14, 2024 20:41 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionRestricted Stock Units · Derivative	76,453	$0.00	$0.00	Disclosure SEC source: 0001628280-24-023247 · wk-form4_1715719263.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. F2 · derivative.expiration_date: On May 9, 2023, the reporting person was granted 76,453 restricted stock units vesting on May 10, 2024. Read SEC document
May 10, 2024 Filed May 14, 2024 20:41 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	76,453	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-023247 · wk-form4_1715719263.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document
May 02, 2024 Filed May 6, 2024 21:23 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GrantRestricted Stock Units · Derivative	40,258	$0.00	$0.00	Disclosure SEC source: 0001628280-24-020722 · wk-form4_1715030598.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,258 Underlying: Class A Common Stock · 40,258 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document
December 06, 2023 Filed Dec 8, 2023 00:55 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GrantOptions (right to buy) · Derivative	35,000	$0.00 Strike: $3.13	$0.00	Disclosure SEC source: 0001062993-23-022118 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer's next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document
August 11, 2023 Filed Aug 14, 2023 21:10 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon Warrants (right to buy) · Derivative	51,813	Not disclosed Strike: $3.86	Not disclosed	Disclosure SEC source: 0000950170-23-042536 · ownership.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,813 Underlying: Common Stock · 51,813 shares Expires 2028-08-11 F1 · shares: Represents shares of common stock, par value $0.0001 per share (the "Common Stock") purchased together with common warrants to purchase shares of Common Stock in the Issuer's registered underwritten offering on August 11, 2023 for a purchase price of $1.93. F1 · price: Represents shares of common stock, par value $0.0001 per share (the "Common Stock") purchased together with common warrants to purchase shares of Common Stock in the Issuer's registered underwritten offering on August 11, 2023 for a purchase price of $1.93. Read SEC document
August 11, 2023 Filed Aug 14, 2023 21:10 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	PurchaseCommon Stock	51,813	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-23-042536 · ownership.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,097 F1 · shares: Represents shares of common stock, par value $0.0001 per share (the "Common Stock") purchased together with common warrants to purchase shares of Common Stock in the Issuer's registered underwritten offering on August 11, 2023 for a purchase price of $1.93. F1 · price: Represents shares of common stock, par value $0.0001 per share (the "Common Stock") purchased together with common warrants to purchase shares of Common Stock in the Issuer's registered underwritten offering on August 11, 2023 for a purchase price of $1.93. F2 · balance_after: The reported number of shares has been adjusted to reflect the impact of the Issuer's 17-for-1 reverse stock split completed on July 26, 2023. Read SEC document
June 09, 2023 Filed Jun 13, 2023 12:07 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	PurchaseCommon Stock	21,858	$0.29	$6,284.18	Disclosure SEC source: 0001615594-23-000047 · primary_doc.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,858 F1 · price: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.2751 to $0.30, inclusive. Read SEC document
June 08, 2023 Filed Jun 9, 2023 14:26 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	PurchaseCommon Stock	25,000	$0.30	$7,400.00	Disclosure SEC source: 0001615594-23-000046 · primary_doc.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 F1 · price: The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from $0.29 to $0.30, inclusive. Read SEC document
May 16, 2023 Filed May 17, 2023 16:25 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	PurchaseCommon Stock	32,534	$0.27	$8,924.08	Disclosure SEC source: 0001615594-23-000033 · primary_doc.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.2601 to $0.279, inclusive. Read SEC document
May 15, 2023 Filed May 16, 2023 15:30 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	PurchaseCommon Stock	44,026	$0.25	$10,856.81	Disclosure SEC source: 0001615594-23-000032 · primary_doc.xml · nonDerivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,466 F2 · price: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.227 to $0.2598, inclusive. Read SEC document
May 12, 2023 Filed May 16, 2023 15:30 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	PurchaseCommon Stock	23,440	$0.24	$5,513.09	Disclosure SEC source: 0001615594-23-000032 · primary_doc.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,440 F1 · price: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.228 to $0.244, inclusive. Read SEC document
May 10, 2023 Filed May 11, 2023 20:15 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionRestricted Stock Units · Derivative	80,128	$0.00	$0.00	Disclosure SEC source: 0001209191-23-028734 · doc4.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. F3 · derivative.expiration_date: On May 9, 2022 the reporting person was granted 80,128 restricted stock units vesting on May 10, 2023. Read SEC document
May 10, 2023 Filed May 11, 2023 20:15 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	80,128	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-028734 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document
May 09, 2023 Filed May 11, 2023 20:15 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GrantRestricted Stock Units · Derivative	76,453	$0.00	$0.00	Disclosure SEC source: 0001209191-23-028734 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,453 Underlying: Class A Common Stock · 76,453 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document
December 07, 2022 Filed Dec 10, 2022 00:22 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GrantOptions (right to buy) · Derivative	12,000	$0.00 Strike: $0.17	$0.00	Disclosure SEC source: 0001062993-22-023659 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer's next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document
May 09, 2022 Filed May 10, 2022 22:42 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	GrantRestricted Stock Units · Derivative	80,128	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028155 · doc4.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 Underlying: Class A Common Stock · 80,128 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document
May 08, 2022 Filed May 10, 2022 22:42 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionRestricted Stock Units · Derivative	35,406	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028155 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. F2 · derivative.expiration_date: On May 5, 2021 the reporting person was granted 35,406 restricted stock units vesting on May 8, 2022. Read SEC document
May 08, 2022 Filed May 10, 2022 22:42 UTC	Amneal Pharmaceuticals, Inc. AMRX · Entity 820	Exercise / conversionClass A Common Stock	35,406	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-028155 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document
December 30, 2021 Filed Jan 3, 2022 20:12 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $0.56	$0.00	Disclosure SEC source: 0001415889-22-000087 · form4-01032022_050107.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-30 F1 · derivative.exercise_date: The options vest 1/12 monthly on the 30th of each month for one year (until December 30, 2022). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $30.47	Not disclosed	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · derivative · entry 7 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	21,000	Not disclosed Strike: $21.61	Not disclosed	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · derivative · entry 6 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	33,000	Not disclosed Strike: $15.44	Not disclosed	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · derivative · entry 5 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $14.76	Not disclosed	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	8,000	Not disclosed Strike: $14.13	Not disclosed	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Disposition to issuerRestricted Stock Units · Derivative	3,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3 · price: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). F3 · derivative.expiration_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). Read SEC document
December 28, 2021 Filed Dec 29, 2021 21:18 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	OtherCommon Stock	4,666	$38.25	$178,474.50	Disclosure SEC source: 0001399529-21-000195 · wf-form4_164081270887814.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document
December 08, 2021 Filed Dec 10, 2021 23:56 UTC	Benitec Biopharma Inc. BNTC · Entity 5596	GrantOptions (right to buy) · Derivative	12,000	$0.00 Strike: $2.99	$0.00	Disclosure SEC source: 0001062993-21-012696 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-12-08 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer's next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document
October 21, 2021 Filed Oct 25, 2021 10:59 UTC	Ampio Pharmaceuticals, Inc. AMPE · Entity 112383	GrantStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $1.67	$0.00	Disclosure SEC source: 0001415889-21-004956 · form4-10252021_071011.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-10-13 F1 · derivative.exercise_date: The stock options vest as to 1/36 of the underlying shares monthly on the 13th day of each month for three years (until October 13, 2024). The vesting commencement date is October 13, 2021. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:33 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantDirector Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $30.47	$0.00	Disclosure SEC source: 0001399529-21-000106 · wf-form4_162311601071532.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-02 F4 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:33 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantRestricted Stock Units · Derivative	3,333	$0.00	$0.00	Disclosure SEC source: 0001399529-21-000106 · wf-form4_162311601071532.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. F3 · derivative.expiration_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:33 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Exercise / conversionRestricted Stock Units · Derivative	4,666	$0.00	$0.00	Disclosure SEC source: 0001399529-21-000106 · wf-form4_162311601071532.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. F2 · derivative.expiration_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. Read SEC document
June 03, 2021 Filed Jun 8, 2021 01:33 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Exercise / conversionCommon Stock	4,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001399529-21-000106 · wf-form4_162311601071532.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.